New shot aims to tame blood disorders

NCT ID NCT07083960

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 31 times

Summary

This early-stage trial tests a new drug called OM336 for people with autoimmune cytopenias, where the immune system attacks blood cells. The study includes 32 adults with conditions like immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA) who have not responded to prior treatments. The main goal is to check the drug's safety and how the body processes it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AIHA - COLD AUTOIMMUNE HEMOLYTIC ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Icon Cancer Center South Brisbane

    RECRUITING

    Brisbane, Queensland, 4066, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Liverpool Hospital

    RECRUITING

    Sydney, New South Wales, 2107, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Canberra Hospital

    RECRUITING

    Canberra, Australian Capital Territory, 2605, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.